Compare CSTM & IRON Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | CSTM | IRON |
|---|---|---|
| Founded | 2010 | 2017 |
| Country | France | United States |
| Employees | N/A | N/A |
| Industry | Metal Fabrications | Biotechnology: Pharmaceutical Preparations |
| Sector | Industrials | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 3.1B | 3.0B |
| IPO Year | 2013 | N/A |
| Metric | CSTM | IRON |
|---|---|---|
| Price | $22.95 | $76.47 |
| Analyst Decision | Buy | Strong Buy |
| Analyst Count | 2 | 13 |
| Target Price | $23.50 | ★ $108.85 |
| AVG Volume (30 Days) | ★ 1.3M | 510.0K |
| Earning Date | 02-19-2026 | 02-26-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | ★ N/A |
| EPS | ★ 0.79 | N/A |
| Revenue | ★ $7,969,000,000.00 | N/A |
| Revenue This Year | $9.76 | N/A |
| Revenue Next Year | $7.28 | N/A |
| P/E Ratio | $29.09 | ★ N/A |
| Revenue Growth | ★ 11.22 | N/A |
| 52 Week Low | $7.33 | $30.82 |
| 52 Week High | $23.64 | $99.50 |
| Indicator | CSTM | IRON |
|---|---|---|
| Relative Strength Index (RSI) | 74.72 | 44.36 |
| Support Level | $21.61 | $73.77 |
| Resistance Level | $23.64 | $81.90 |
| Average True Range (ATR) | 0.72 | 3.55 |
| MACD | 0.12 | 0.24 |
| Stochastic Oscillator | 85.10 | 59.07 |
Constellium SE is engaged in the design and manufacture of rolled and extruded aluminium products, serving the packaging, aerospace, automotive, defence and other transportation and industry end-markets. The business is organized into three operating segments: the Packaging and Automotive Rolled Products segment which includes the production of rolled aluminium sheet products in European and North American facilities; the Aerospace and Transportation segment includes the production of rolled aluminium products and very limited volumes of extruded products in European and North American facilities; the Automotive Structures and Industry segment includes the production of extruded aluminium products and aluminium structural components.
Disc Medicine Inc is a clinical-stage biopharmaceutical company focused on the discovery, development, and commercialization of novel treatments for hematologic diseases. It aims to modify fundamental biological pathways associated with the formation and function of red blood cells, specifically heme biosynthesis and iron homeostasis. Its pipeline includes bitopertin for erythropoietic porphyrias (EPs) including erythropoietic protoporphyria (EPP), X-linked protoporphyria (XLP), and Diamond-Blackfan Anemia (DBA); DISC-0974 for the treatment of anemia of myelofibrosis (MF) and anemia of chronic kidney disease (CKD); and DISC-3405 for the treatment of polycythemia vera (PV) and other hematologic disorders. In addition, the Company's preclinical programs include DISC-0998.